# US 2019/0376139 A1 · Methods for assessing risk of developing a viral disease using a genetic test

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376139 A1
- Document ID: US20190376139A1
- Status: Published application
- Kind: A1
- Application number: 16/542,742
- Filed: 2019-08-16
- Published: 2019-12-12
- Earliest claimed: 2017-02-03
- Assignees: PML Screening, LLC; Universite Paris-Sud; Assistance Publique-HôPitaux De Paris (Aphp); Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Applicants: PML Screening, LLC; The Université Paris-Sud; The Assistance Publique - Hopitaux de Paris (APHP); The Institut National de la Santé et de la Recherche Médicale (INSERM)
- Inventors: ELI HATCHWELL; Peggy S. Eis; Edward B. Smith, III; Yassine Taoufik
- Web page: https://patentgrep.com/patent/US20190376139A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C07K 16/2839: {against the integrin superfamily}
- G01N 33/56983: {Viruses}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2333/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

## Claims

### Claim 1

A method of treating a condition in a subject in need of immunosuppressive therapy, comprising: administering a therapeutically effective amount of an immunosuppressive agent to the subject, wherein the subject has a decreased risk of progressive multifocal leukoencephalopathy (PML) due to an infection of the brain by John Cunningham virus (JCV), wherein the subject's decreased risk is associated with the absence of one or more genetic variations in the subject, wherein the subject has been tested for a presence of the one or more genetic variations with a genetic assay and has been identified as not having the one or more genetic variations, wherein the one or more genetic variations have an odds ratio (OR) of 2 or more, and wherein the OR is:
[DD/DN]/[ND/NN],
wherein:
DD is the number of subjects in a diseased cohort of subjects with the one or more genetic variations;
DN the number of subjects in the diseased cohort without the one or more genetic variations;
ND is the number of subjects in a non-diseased cohort of subjects with the one or more genetic variations; and
NN is the number of subjects in the non-diseased cohort without the one or more genetic variations; and
wherein the diseased cohort of subjects have PML and the non-diseased cohort of subjects do not have PML.

### Claim 2 (depends on 1)

The method of claim 1, wherein the condition is multiple sclerosis or a relapsing form of multiple sclerosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the condition is Crohn's disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immunosuppressive agent is natalizumab, dimethyl fumarate or fingolimod.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more genetic variations comprises chr19:7712287 G>C, chr1:92946625 G>C, chr1:42047208 C>G, chr22:23915583 T>C or chr6:51798908 C>T; wherein chromosome positions of the one or more genetic variations are defined with respect to UCSC hg19.

### Claim 6 (depends on 1)

The method of claim 1, wherein a first genetic variation of the one or more genetic variations comprises chr19:7712287 G>C, chr1:92946625 G>C, chr1:42047208 C>G, chr22:23915583 T>C or chr6:51798908 C>T; and wherein a second genetic variation of the one or more genetic variations comprises chr2:163136505 C>G, chr11:67818269 G>A, chr22:23915745 G>A or chr16:81942175 A>G, wherein the chromosome positions are defined with respect to UCSC hg19.

### Claim 7 (depends on 1)

The method of claim 1, wherein the one or more genetic variations disrupts or modulates a STXBP2 gene, a SERPIN gene, an ATM gene, a DNER gene, a GFI1 gene, a HIVEP3 gene, an IGLL1 gene, a LIG1 gene, a LRBA gene, a NQO2 gene, a PKHD1 gene or a TAP1 gene.

### Claim 8 (depends on 7)

The method of claim 7, wherein a first genetic variation of the one or more genetic variations disrupts or modulates a STXBP2 gene, a SERPIN gene, an ATM gene, a DNER gene, a GFI1 gene, a HIVEP3 gene, an IGLL1 gene, a LIG1 gene, a LRBA gene, a NQO2 gene, a PKHD1 gene or a TAP1 gene; and wherein a second genetic variation of the one or more genetic variations disrupts or modulates a corresponding gene according to Tables 3 and 6.

### Claim 9 (depends on 7)

The method of claim 7, wherein a first genetic variation of the one or more genetic variations disrupts or modulates a STXBP2 gene, a SERPIN gene, an ATM gene, a DNER gene, a GFI1 gene, a HIVEP3 gene, an IGLL1 gene, a LIG1 gene, a LRBA gene, a NQO2 gene, a PKHD1 gene or a TAP1 gene; and wherein a second genetic variation of the one or more genetic variations disrupts or modulates a corresponding gene according to Tables 25A, 25B, and 26.

### Claim 10 (depends on 7)

The method of claim 7, wherein a first genetic variation of the one or more genetic variations disrupts or modulates a STXBP2 gene, a SERPIN gene, an ATM gene, a DNER gene, a GFI1 gene, a HIVEP3 gene, an IGLL1 gene, a LIG1 gene, a LRBA gene, a NQO2 gene, a PKHD1 gene or a TAP1 gene; and wherein a second genetic variation of the one or more genetic variations disrupts or modulates an IFIH1 gene, an IGLL1 gene, a PLCG2 gene or a TCIRG1 gene.

### Claim 11 (depends on 1)

The method of claim 1, wherein the diseased cohort of subjects, the non-diseased cohort of subjects, or both cohorts of subjects are ethnically matched.

### Claim 12 (depends on 1)

The method of claim 1, wherein the one or more genetic variations have an odds ratio (OR) of 6 or more.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject has been identified as not having one or more other genetic variations that disrupt or modulate a corresponding gene according to Tables 1, 3 and 6-10.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is identified as not having one or more other genetic variations that disrupt or modulate a corresponding gene according to Tables 19-24.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject has been tested with a JCV-antibody test, a CD62L test, or a CSF IgM oligoclonal bands test.

### Claim 16 (depends on 1)

The method of claim 1, wherein the one or more genetic variations comprise two or more genetic variations.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method further comprises testing the subject for the presence of the one or more genetic variations with the genetic assay prior to the administering.

### Claim 18 (depends on 17)

The method of claim 17, wherein the genetic assay comprises microarray analysis, PCR, sequencing, nucleic acid hybridization, or any combination thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein the one or more genetic variations disrupt or modulate one or more immune response-related genes or immune pathway related genes.

### Claim 20 (depends on 17)

The method of claim 17, wherein prior to testing the subject for the presence of the one or more genetic variations with the genetic assay the method further comprises obtaining biological samples from subjects with PML and (a) confirming each biological sample is not a duplicate of any other biological sample based on nucleic acid information of the biological samples or (b) determining a sex genotype for each biological sample based on nucleic acid information of the biological samples, and confirming the sex genotype of each biological sample is the same as a sex phenotype of the subject with PML from which the biological sample was obtained.
